dazzle ai | $8,000,000 | (Jan 7, 2026)
Tesoro XP, Inc. | $5,400,000 | (Jan 7, 2026)
Lemon Slice | $10,500,000 | (Jan 7, 2026)
ImmuneWalk Therapeutics
United States
- Pearl River, New York
- 08/05/2025
- Seed
- $7,000,000
ImmuneWalk Therapeutics is a private clinical-stage company focused on development of novel therapies for chronic inflammatory diseases. Our Monocyte Targeting Technology (MTT) is designed to selectively block the migration (`walking`) of monocytes from the blood stream into inflamed tissues. Our lead candidate, IW-601, is a proprietary monoclonal antibody that is engineered to specifically prevent monocytes from exiting the blood stream and traveling to inflammatory sites. IW-601 is designed to offer a novel and differentiated approach in the landscape of current anti-inflammatory agents.
With clear disease-modifying activity in models of Multiple Sclerosis, Rheumatoid Arthritis, Inflammatory Bowel Disease and Non- Alcoholic Steatohepatitis, in addition to proof-of-concept from patient’s cells, we are advancing IW-601 to a Ph1 clinical trial.
- Industry Biotechnology Research
- Website https://immunewalk.com/
- LinkedIn https://www.linkedin.com/company/immunewalk-therapeutics/
Array Labs | $20,000,000 | (Jan 7, 2026)
Lyte | $107,000,000 | (Jan 7, 2026)
Lucidean | $18,000,000 | (Jan 7, 2026)
CHAMP | $55,000,000 | (Jan 7, 2026)
Truemed | $34,000,000 | (Jan 7, 2026)
Coinbax | $4,200,000 | (Jan 7, 2026)
Peripheral Labs | $3,600,000 | (Dec 23, 2025)
Ciphero | $2,500,000 | (Dec 23, 2025)
Givefront | $2,000,000 | (Dec 23, 2025)